TruAlt Bioenergy Limited disclosed that its promoter group entity, Nirani Holdings Private Limited, created a pledge on 14,00,000 equity shares with Jio Credit Limited. The transaction, reported on September 24, 2026, serves as security for debt availed by the company's promoters.

The pledged shares represent 1.63% of the total share capital of TruAlt Bioenergy. Nirani Holdings Private Limited holds a total of 16,57,411 shares, constituting 1.93% of the company's equity. Prior to this event, none of the promoter group's holdings were encumbered.

Purpose of the pledge

The shares were pledged by Nirani Holdings Private Limited as security for a debt facility extended by Jio Credit Limited (formerly known as Jio Finance Limited). The underlying loan was availed by Mr. Vijaykumar Nirani and Mr. Vishal Nirani, the promoters of TruAlt Bioenergy.

According to the disclosure filed under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, and SEBI (Prohibition of Insider Trading) Regulations, 2015, the proceeds from this debt were utilized for financing the acquisition of additional shares in TruAlt Bioenergy. The stated objective of this acquisition was to increase the promoters' shareholding in the company.

Encumbrance details

The creation of the encumbrance occurred on September 22, 2026. The disclosure confirms that while the specific block of 14 lakh shares is now pledged, the total holding of the promoter group remains unchanged at 16,57,411 shares. The value of the transaction was disclosed as ₹58.10 crore.

What the numbers show

A significant portion of the promoter group's holding is now leveraged. The pledged amount of 14,00,000 shares constitutes approximately 84% of Nirani Holdings Private Limited's total holding of 16,57,411 shares. This high ratio indicates that the majority of the promoter group's equity stake in TruAlt Bioenergy is currently encumbered as collateral for the debt raised to fund their share acquisition.

TruAlt Bioenergy Limited has paid ₹5.49 lakh in fines to BSE and NSE to resolve non-compliance issues related to board composition and meeting intimations. The company restored regulatory compliance by appointing Dr. Sarvamangala R Patil as a Non-Executive Independent Woman Director during its board meeting on September 22, 2026.

The penalties stemmed from violations of Regulation 17(1) and Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board acknowledged that the delay in appointing a woman director was not intentional but resulted from the time required to identify a suitable candidate with the requisite qualifications and independence.

Regulatory Fines and Compliance Restoration

The exchange notices highlighted two specific instances of non-compliance:

The Board noted that the lapse under Regulation 29 was procedural and inadvertent. Upon finalizing the candidate selection, Dr. Patil was appointed, thereby satisfying the requirement under Regulation 17(1). The Company Secretary confirmed that the applicable fines were paid within the stipulated timeline to avoid further penal actions such as freezing of promoter shareholding or trading suspension.

Subsidiary Investments and Strategic Context

In the same board meeting, the company approved additional investments totaling ₹29.69 crore in two subsidiaries to support growth plans. This capital infusion targets Leafiniti Bioenergy Private Limited and TruAlt Sumi Gas Private Limited.

The board authorized an investment of ₹21.42 crore in Leafiniti Bioenergy Private Limited through the subscription of 2,14,20,000 equity shares at a par value of ₹10 each. TruAlt Bioenergy currently holds a 51% stake in this joint venture with GAIL India Limited, which produces compressed biogas and allied products.

Additionally, an investment of ₹8.27 crore was approved in TruAlt Sumi Gas Private Limited (formerly TruAlt Gas Private Limited). This involves acquiring 24,31,830 equity shares at ₹34 per share, including a premium of ₹24 per share. This entity is a joint venture with Sumitomo Corporation, Japan, and has not yet commenced operations.

Subsidiary Performance Metrics

Leafiniti Bioenergy Private Limited, incorporated in February 2020, has shown significant revenue growth over the last three financial years:

TruAlt Sumi Gas Private Limited, incorporated in September 2024, remains pre-operational, with no turnover details available yet.

Governance Updates

Dr. Sarvamangala R Patil brings over two decades of experience in biotechnology, academic leadership, and government advisory roles. Her appointment is subject to shareholder approval via a special resolution for a term from September 22, 2026, to September 21, 2027. Mr. Deepak Sadhu, a Practising Company Secretary, was appointed as the Scrutinizer for the postal ballot process, with NSDL serving as the e-voting agency.

What the Numbers Show

The combined data reveals a dual focus on regulatory hygiene and operational expansion. While the company faced governance penalties totaling ₹5.49 lakh, it simultaneously committed ₹29.69 crore to subsidiary investments. The revenue jump in Leafiniti Bioenergy from ₹2,760.74 lakh in FY25 to ₹4,043.09 lakh in FY26 underscores the strategic importance of this subsidiary, justifying the majority of the new capital infusion at par value. In contrast, the premium-priced entry into TruAlt Sumi Gas reflects early-stage valuation dynamics for a non-operational venture.